Review of Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination

Content of review 1, reviewed on October 29, 2021

This retrospective study in China aimed to: (1) determine the prevalence of linezolid (LZD) resistance among multidrug-resistant tuberculosis (MDR-TB)-infected patients; (2) monitor for dynamic LZD susceptibility changes during anti-TB treatment; and (3) explore molecular mechanisms conferring LZD resistance. The two key results are: - LZD resistance occurred in 6.9% of MDR-TB patients in an MDR-TB cohort in China. - Low rate of acquired LZD resistance was noted in MDR-TB treated with BDQ-LZD combination.

I have no conflicts of interest

Source

References

Jian, D., Jingtao, G., Yanhong, Y., Qingfeng, L., Guanghong, B., Wei, S., Mengqiu, G., Yuhong, L., Lu, W., Yufeng, W., Zhongtan, X., Fengmin, H., Liang, L., Yu, P. 2021. Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination. Frontiers in Microbiology.

Post-publication Review of

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination

Reviewed On October 29, 2021

Reviewed by

Actions

Content of review 1, reviewed on October 29, 2021

Source

References